Rasagiline Pharmacokinetics in CYP1A2 Variant Healthy Smokers & Non-smokers in Different Doses

OBJECTIVES: Rasagiline, a drug for Parkinson’s disease is metabolized by CYP1A2 enzyme. The objective of the study was to investigate the influence of cytochrome P450 1A2 variants and smoking status of healthy individuals on the pharmacokinetics of rasagiline. METHODS: A comparative, open label, int...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilal, Rabiea, Ahmad, Naseem Saud, Zaffar, Sehrish, Mazhar, Muhammad Usama, Siddiqui, Waqar Ahmed, Tariq, Saba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publications 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002453/
https://www.ncbi.nlm.nih.gov/pubmed/35480532
http://dx.doi.org/10.12669/pjms.38.3.4940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002453/
https://www.ncbi.nlm.nih.gov/pubmed/35480532
http://dx.doi.org/10.12669/pjms.38.3.4940

Ejemplares similares